Source comparison
AOD9604 vs Full hGH: Regulatory and Functional Differences
AOD9604 (same as AOD-9604) is classified as a peptide fragment, not a growth hormone analogue, because it does not replicate hGH's full receptor-binding profile. This distinction matters legally and mechanistically. Growth hormone analogues. Including sermorel
This comparison does not assign a generated winner or score.
- AOD9604 (same as AOD-9604) is classified as a peptide fragment, not a growth hormone analogue, because it does not replicate hGH's full receptor-binding profile. This distinction matters legally and mechanistically. Growth hormone analogues. Including sermorelin, tesamorelin, and CJC-1295. Are regulated as hormone therapies due to their capacity to elevate endogenous hGH or IGF-1. AOD9604 bypasses this classification because it lacks the structural domain required to activate hGH receptors or stimulate pituitary secretion. Regulatory bodies treat it as a research peptide rather than a controlled therapeutic hormone.
- Functionally, the differences are measurable. Full hGH administration increases lean muscle mass, bone density, and collagen synthesis. Effects mediated by IGF-1 upregulation in target tissues. AOD9604 produces none of these outcomes. A Phase IIa trial conducted at Monash University enrolled 300 obese adults and found that 1 mg daily AOD9604 reduced visceral fat mass by 2.6% over 12 weeks compared to placebo, but lean body mass and fasting glucose remained unchanged. Participants on full hGH therapy in comparable trials show lean mass gains of 3–5% alongside glucose elevation and joint stiffness. Outcomes absent in AOD9604 cohorts.
- The absence of growth effects also eliminates several adverse event risks. Growth hormone therapy is contraindicated in patients with active malignancy due to IGF-1's mitogenic properties. AOD9604 does not elevate IGF-1 and does not promote cellular proliferation in preclinical carcinogenesis models. This selectivity makes it a research tool for studying adipocyte metabolism without confounding endocrine variables introduced by full hGH. Researchers examining fat oxidation pathways, beta-adrenergic receptor function, or lipid mobilisation mechanisms use AOD9604 specifically because it isolates lipolytic signalling from growth-related pathways.
- Amino Acid Length
- 15 residues (C-terminal fragment)
- 191 residues (full sequence)
- Shorter fragment allows isolated lipolysis study
- IGF-1 Elevation
- None. No hepatic hGH receptor binding
- Significant. JAK2-STAT5 pathway activation
- AOD9604 eliminates growth confounders in metabolic models
- Half-Life (subcutaneous)
- ~8 hours (rapid renal clearance)
- 2–4 hours (intact hGH); up to 6–8 days (modified analogues)
- Twice-daily dosing vs once-daily or weekly protocols
- Lipolytic Effect
- Direct beta-3 adrenergic receptor agonism
- Indirect via catecholamine potentiation + beta-receptor sensitisation
- AOD9604 bypasses sympathetic nervous system requirement
- Lean Mass Impact
- No change in skeletal muscle or bone density
- 3–5% lean mass increase over 12–24 weeks
- Fragment does not trigger anabolic tissue growth
- Glucose Metabolism
- No effect on fasting glucose or insulin sensitivity
- Elevates fasting glucose 5–10 mg/dL; reduces insulin sensitivity
- AOD9604 avoids diabetogenic risk seen with hGH therapy
- Professional Assessment
- Selective lipolytic tool for adipocyte research. Useful when growth signalling must be excluded
- Broad metabolic and anabolic effects. Appropriate when studying whole-body hGH physiology